116409-29-1
116409-29-1 structure
- Name: NSC 370284
- Chemical Name: 6-[pyrrolidin-1-yl-(3,4,5-trimethoxyphenyl)methyl]-1,3-benzodioxol-5-ol
- CAS Number: 116409-29-1
- Molecular Formula: C21H25NO6
- Molecular Weight: 387.42600
- Catalog: Signaling Pathways JAK/STAT Signaling STAT
- Create Date: 2017-12-29 10:28:05
- Modify Date: 2024-01-10 16:42:48
-
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5. NSC-370284 has low cytotoxicity[1].
| Name | 6-[pyrrolidin-1-yl-(3,4,5-trimethoxyphenyl)methyl]-1,3-benzodioxol-5-ol |
|---|
| Description | NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5. NSC-370284 has low cytotoxicity[1]. |
|---|---|
| Related Catalog | |
| Target |
STAT3 STAT5 TET1 |
| In Vitro | NSC-370284 (0-500 nM；24 h 或 48 h) 通过靶向 STAT3/5 抑制 MONOMAC-6、THP-1、KOCL-48 和 KASUMI-1 急性髓系白血病 (AML) 细胞活力。NSC-370284 显著下调 TET1 转录水平[1]。 Cell Viability Assay[1] Cell Line: AML cell lines including MONOMAC-6, THP-1, KOCL-48, and KASUMI-1 Concentration: 0, 25, 50, 200 or 500 nM Incubation Time: 24 h or 48 h Result: Showed inhibitory for AML cells viability and TET1 transcription. |
| In Vivo | NSC-370284 (2.5 mg/kg；腹腔注射，每天一次，持续 10 天) 改善了 MLL-AF9 急性髓系白血病 (AML) 小鼠模型外周血 (PB)、骨髓 (BM)、脾和肝组织的病理形态学[1]。 Animal Model: C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice[1]. Dosage: 2.5 mg/kg. Administration: Intraperitoneal injection, once daily, for 10 days. Result: Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice. |
| References |
| Density | 1.276g/cm3 |
|---|---|
| Boiling Point | 515.2ºC at 760mmHg |
| Molecular Formula | C21H25NO6 |
| Molecular Weight | 387.42600 |
| Flash Point | 265.4ºC |
| Exact Mass | 387.16800 |
| PSA | 69.62000 |
| LogP | 3.26980 |
| Vapour Pressure | 3.09E-11mmHg at 25°C |
| Index of Refraction | 1.598 |
|
~90%
116409-29-1 |
| Literature: Journal of Heterocyclic Chemistry, , vol. 25, # 1 p. 89 - 96 |
| Precursor 3 | |
|---|---|
| DownStream 10 | |
![6-ethoxy-6-methyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]chromene structure](https://www.chemsrc.com/caspic/275/116409-28-0.png)
![6-methoxy-6,7-dimethyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]chromene structure](https://www.chemsrc.com/caspic/013/116409-22-4.png)
![1-[7-methyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-6H-[1,3]dioxolo[4,5-g]chromen-6-yl]pyrrolidine structure](https://www.chemsrc.com/caspic/351/116409-04-2.png)
![7-methyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-6H-[1,3]dioxolo[4,5-g]chromen-6-ol structure](https://www.chemsrc.com/caspic/313/116409-05-3.png)
![1-[6,7-dimethyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]chromen-6-yl]pyrrolidine structure](https://www.chemsrc.com/caspic/089/116409-20-2.png)
![6-methyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]chromen-6-ol structure](https://www.chemsrc.com/caspic/361/116409-26-8.png)
![1-[6-methyl-8-(3,4,5-trimethoxyphenyl)-8H-[1,3]dioxolo[4,5-g]chromen-7-yl]ethanone structure](https://www.chemsrc.com/caspic/254/117233-19-9.png)
![1-[6-methoxy-6-methyl-8-(3,4,5-trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]chromen-7-yl]ethanone structure](https://www.chemsrc.com/caspic/165/117211-88-8.png)